Endometrial Cancers Clinical Trial
Official title:
Screening and Identification of Novel Diagnostic and Prognostic Biomarkers on Endometrial Cancers
Ovarian cancer is the first mortality rate of gynecologic malignancies. The incidence of
ovarian cancer increased in recent 10 years and it has become the ninth cause of
malignancies in the women in Taiwan. From the above-mentioned data, ovarian cancer indeed is
a disease that should be respected, however, there were only few of research work focusing
on it in Taiwan. Despite the widespread use of aggressive cytoreductive surgery and the
introduction of chemotherapy regimens, the overall survival has changed little over the last
two decades. The basic problem in treating epithelial ovarian cancer is that once it has
spread beyond the ovary, it is exceedingly difficult to control and ultimately to cure. More
than 70% of ovarian cancer patients were advanced stage when diagnosed. To study the
mechanisms of carcinogenesis, progression, and metastasis of ovarian cancer will help us
understand this disease and develop new treatment strategies for ovarian cancer in the
future.
We have established an ascitogenic itnraperitoneal tumor cell line-WF3 in the mouse model in
our previous two-year project of NSC grant (grant number (NSC90-2314-B-002-457 and
NSC91-2341-B-002-315). Our group found that, mesothelin, this molecule is highly related
with the carcinogenesis, tumor progression and tumor metastasis in our animal model and
human cancer tissues. To further evaluate the role of mesothelin in ovarian cancer and
elucidate the potential of mesothelin as a target antigen for immunotherapy,
n/a
Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science